| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 11/03/2004 | CN1173957C Substituted piperazones and their therapeutic use |
| 11/03/2004 | CN1173709C Soft package type enclosed hemodialysis liquid, its special package bag and its preparation method |
| 11/02/2004 | US6812328 High cooperativity in oxygen binding; rhb (beta n108q) exhibits enhanced stability against autoxidation; wherein the asparagine residue at position 108 of the beta-chains is replaced by a glutamine residue; genetic engeineering; |
| 11/02/2004 | US6812253 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical |
| 11/02/2004 | US6812250 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 11/02/2004 | US6812235 2-acylamino- beta -alanine derivatives and a pharmaceutically acceptable salt, useful as fibrinogen receptor antagonists |
| 11/02/2004 | US6812221 Immobilization |
| 11/02/2004 | US6811778 Method for improving oxygen transport by stored red blood cells |
| 10/28/2004 | WO2004092218A1 Process for producing recombinant antithrombin |
| 10/28/2004 | WO2004091723A1 Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
| 10/28/2004 | WO2004091643A1 Agent for increasing granulocyte macrophage colony stimulating factor |
| 10/28/2004 | WO2004091635A1 Remedy for endometriosis and gynecologic diseases |
| 10/28/2004 | WO2004091628A1 Receptor antagonist |
| 10/28/2004 | WO2004091613A2 Substituted phenyl acetamides and their use as protease inhibitors |
| 10/28/2004 | WO2004072643A3 Diagnostics and therapeutics for diseases associated with glucagon-like peptide 2 receptor (glp2r) |
| 10/28/2004 | WO2004043481A3 Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto |
| 10/28/2004 | WO2004024094A3 Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels |
| 10/28/2004 | WO2001081540A3 Growth factor which acts through erb b-4 rtk |
| 10/28/2004 | US20040215292 Photodynamic treatment of targeted cells |
| 10/28/2004 | US20040215019 Substituted isoindoles and the e use thereof |
| 10/28/2004 | US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders |
| 10/28/2004 | US20040214894 adminstering to a patient for suppressing, ameliorating, or treating methionine-induced anemia a threonine or salts; side effect reduction |
| 10/28/2004 | US20040214864 Novel compounds |
| 10/28/2004 | US20040214839 administering prostaglandin or agonist thereof and type IV selective phosphodiesterase (PDE) inhibitor to induce tolerance to antigens |
| 10/28/2004 | US20040214820 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 10/28/2004 | US20040214759 Compositions and methods of use for a fibroblast growth factor |
| 10/28/2004 | US20040214275 Von willebrand factor (vmf)-cleaving enzyme |
| 10/28/2004 | US20040214261 culturing genetically modified microorganism containing polyglutamyl hydrolase (from rodents, mammals, or humans) activity to enhance generation of monoglutamyl folate; food processing; dairy products |
| 10/28/2004 | US20040213797 Conjugates for the modulation of immune responses |
| 10/27/2004 | EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 10/27/2004 | EP1470218A2 Corona-virus-like particles comprising functionally deleted genomes |
| 10/27/2004 | EP1470143A1 Compounds that inhibit factor xa activity |
| 10/27/2004 | EP1470137A1 Edg receptor agonists |
| 10/27/2004 | EP1470122A1 Rho-kinase inhibitors |
| 10/27/2004 | EP1470121A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 10/27/2004 | EP1470104A2 Novel compounds that inhibit factor xa activity |
| 10/27/2004 | EP1469891A1 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| 10/27/2004 | EP1469887A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 10/27/2004 | EP1469884A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders |
| 10/27/2004 | EP1469875A1 Compositions and methods for modulating connexin hemichannels |
| 10/27/2004 | EP1469865A2 Hemostatic compositions and methods for controlling bleeding |
| 10/27/2004 | EP1469862A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| 10/27/2004 | EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators |
| 10/27/2004 | EP1469846A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 10/27/2004 | EP1387701B1 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy |
| 10/27/2004 | EP1141022B1 Serine protease inhibitor |
| 10/27/2004 | EP0831877B1 Metabolic effects of certain glutathione analogs |
| 10/27/2004 | CN1541211A Derivatives of N-(arylsulfonyl) beta-aminoacids comprising substituted aminomethyl group, prepn. method thereof and pharmaceutical compsns. contg same |
| 10/27/2004 | CN1541102A Somatostain agonists |
| 10/27/2004 | CN1541099A Arylazo-substituted imidazole for treatment of stress urinary incontinence |
| 10/27/2004 | CN1541090A Prepn. of sustained release pharmaceutical compsn. |
| 10/27/2004 | CN1539466A Hemostatic |
| 10/27/2004 | CN1539464A Capsule of Chinese traditional medicine for treating thrombus |
| 10/27/2004 | CN1539459A Chinese materia medica preparation of recreating blood for curing anaemia and producing method |
| 10/27/2004 | CN1539447A Medicated rehabilitation wine for treating premonitory apoplexy, sequela of apoplexy and obastrcution of qi in chest |
| 10/27/2004 | CN1172952C Mannosan peptide and its prepn and use |
| 10/27/2004 | CN1172948C New pentasaccharides, their methods of production and pharmaceutical compositions containing same |
| 10/27/2004 | CN1172929C Substituted indoles for modulating NFKB activity |
| 10/27/2004 | CN1172671C Medicial composition for oral administration |
| 10/26/2004 | US6809199 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 10/26/2004 | US6809092 1,3,4,5-tetrahydro-2h-2-benzazepin-2-yl derivatives; cysteine protease inhibitors |
| 10/26/2004 | US6809090 Nitrogen monoxide synthase and/or lipidic peroxidation inhibitors |
| 10/26/2004 | US6809077 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration |
| 10/26/2004 | US6808898 Low oxygen affinity mutant hemoglobins |
| 10/26/2004 | US6808706 Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution |
| 10/26/2004 | CA2127215C New use of beta-naphtoquinone derivatives and of their salts for the production of a medicament to inhibit platelet aggregation |
| 10/26/2004 | CA2127214C New use of beta-naphtoquinone derivatives and of their salts for the production of a medicament which accelerate the growth of endothelial cells to inhibit no synthtases |
| 10/26/2004 | CA2080462C Therapeutic uses of actin-binding compounds |
| 10/21/2004 | WO2004089964A1 Lipid-regulating agent and use thereof |
| 10/21/2004 | WO2004089937A1 7-membered heterocyclic derivative |
| 10/21/2004 | WO2004089895A1 Process for the preparation of amorphous calcium salt of atorvastatin |
| 10/21/2004 | WO2004089403A1 Method of removing albumin aggregate and/or contaminated protein |
| 10/21/2004 | WO2004089399A1 Novel uses of rfrp and ot7t022 |
| 10/21/2004 | WO2004089278A2 Sexual hygienic composition |
| 10/21/2004 | WO2004047760A3 Novel chemical compounds |
| 10/21/2004 | WO2003097163A3 Using a selective inos inhibitor for the treatment of respiratory diseases and conditions |
| 10/21/2004 | WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 10/21/2004 | WO2003045228A3 Methods for treating autoimmune disorders, and reagents related thereto |
| 10/21/2004 | WO1995018619A9 Bicyclic fibrinogen antagonists |
| 10/21/2004 | US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 10/21/2004 | US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them |
| 10/21/2004 | US20040209935 Pyrazole-derived kinase inhibitors and uses thereof |
| 10/21/2004 | US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 10/21/2004 | US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors. |
| 10/21/2004 | US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 10/21/2004 | US20040209868 Substituted indoles |
| 10/21/2004 | US20040209863 5-chloro-N-(5-chloropyridin-2-yl)-2-[(4-{(Z)-(dimethylamino)[(methylsulfonyl)imino]methyl}benzoyl)amino]benzamide; treating thromboembolic disorders, optionally with other active agents |
| 10/21/2004 | US20040209845 Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer and specifically acute lymphoblastic leukemia; (E,E)-2-(benzylamido)-3-styrylacrylonitrile for example |
| 10/21/2004 | US20040209843 addtion of a cyclodextrin compound increases the water solubility; storage stable solution; immediately treating symptoms of acute phases of myocardial or a cerebral infarction |
| 10/21/2004 | US20040209802 Administering erythropoietin or derivative to treat diabetes |
| 10/21/2004 | US20040209359 Freeze-dried biocompatible matrix/biological scaffold comprising plasma proteins for use as implants in tissue engineering and biotechnology; wound healing agents |
| 10/21/2004 | US20040209333 administering subtilisins obtained from grampositive bacterial residues that vitamin k2 has been removed using chitosan |
| 10/21/2004 | US20040209324 Comprises genetically altered thrombopoietin for use in treatment of thrombocytopenia; gene therapy and therapeutic proteins |
| 10/21/2004 | US20040209288 Using adjustments in leukotriene biosynthetic profile as tool to diagnosis and treat cardiovasular disorders |
| 10/21/2004 | US20040209264 Comprises nucleotide sequences coding daugther of legless protein for use in identifying modulator for tissue regeneration and repair and the treatment of blood disorders |
| 10/21/2004 | US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability |
| 10/21/2004 | US20040208861 Stromal cell use |
| 10/21/2004 | US20040208786 Autologous coagulant produced from anticoagulated whole blood |
| 10/21/2004 | CA2521855A1 Feminine hygiene composition comprising an equid milk extract |
| 10/20/2004 | EP1468682A1 Therapeutic combinations comprising amlodipine and atorvastatin |